Testing carboplatin or olaparib for gene-linked prostate cancer
Treatments studied
Part of Brain & nervous system, Cancer, Genetic & congenital, Kidney & urinary clinical trials.
This Phase 2 study tests whether carboplatin or olaparib can help people with prostate cancer that has certain DNA repair gene changes. It’s designed for advanced (metastatic) prostate cancer that is growing despite standard hormone-blocking treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You agree to the study and sign consent/permission forms
- You are over age 18 and have prostate cancer (with allowed neuroendocrine features, but not pure small-cell cancer)
- Your cancer is advanced (metastatic castration-resistant) while your testosterone is kept low with hormone therapy
- Your tumor or blood test shows specific DNA repair gene changes (RAD51B, RAD51C, RAD51D, or RAD54L) or a matching inherited gene variant
- You’ve already had at least one prior hormone-therapy drug like abiraterone or enzalutamide (or similar)
- Your blood counts and organ function are strong enough for study treatment (recent lab tests within 28 days)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called talazoparib, either alone or combined with enzalutamide, in people with prostate cancer that has spread and has a specific genetic change. The goal is to see if this treatment can help control the cancer after previous therapies have stopped working.
This trial tests whether adding carboplatin (a chemotherapy drug) to hormone therapy helps men with advanced prostate cancer that has either a BRCA gene mutation or specific neuroendocrine features. The goal is to improve survival and disease control.
This trial uses a blood test (circulating tumor DNA) to see whether PARP inhibitors are working for certain men with advanced prostate cancer. It may help predict which treatment responses are likely and monitor changes over time.
This trial tests a combination of two chemotherapy drugs (carboplatin and docetaxel) for men whose prostate cancer has spread and has specific changes in DNA repair genes. It aims to see if this treatment can help when other hormone therapies have stopped working.
This Phase 2 study tests whether adding a medicine called olaparib to radiation helps men with high-risk prostate cancer. You may receive radiation alone or radiation plus olaparib, and the study looks at whether the combination works better.
This study looks at how men with advanced prostate cancer that has spread are doing while taking the drug olaparib. Researchers want to understand how well the drug works and what happens to patients over time.
Hear when a new Metastatic Castrate Resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.